Don’t Wait for US Legalization, Here Are 4 Cannabis Stocks to Consider Right Now

Earlier in April, the Marijuana Opportunity Reinvestment and Expungement Act (MORE) was narrowly passed by the United States House of Representatives by a vote of 220–204. Marijuana use was legal until 29 U.S. states banned it between 1916 and 1931.

The Marijuana Tax Act of 1937 effectively made cannabis illegal throughout the United States. While it is still illegal on a federal level, most states have legalized the use and sale of medical marijuana. The Drug Enforcement Agency still classifies cannabis as a Schedule I drug, “ with no currently accepted medical use and a high potential for misuse.”

The MORE Act is aimed at federally legalizing cannabis, eliminating federal criminal penalties for those growing, possessing, or distributing cannabis, and expunging nonviolent cannabis convictions. It would also fund criminal and social justice programs to assist communities impacted by decades of over-policing of nonviolent marijuana-related crimes.

The Act faces a challenge in the Senate due to Republican opposition. The New Hampshire Senate voted down two cannabis legalization bills in late April, citing concerns about children, drivers, and irresponsible residents using cannabis if it were legalized.

Even though marijuana is illegal on the federal level, more states are likely to legalize medical and recreational marijuana in the coming years. As of April 2022, 37 states have legalized cannabis for medical use and 18 states have approved recreational marijuana usage for adults.

In addition, medical marijuana has been approved in the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands, and the US Virgin Islands. Furthermore, public support continues to grow, with 68% in favor of nationwide legalization, including 83% of Democrats, 50% of Republicans, and 71% of independents, according to a Gallup Poll.

In a Harris Poll from 2021, 66% of respondents supported marijuana legalization, with nearly 80% of Gen X and Millennials supporting it, compared to 48% of Baby Boomers. As legalization and decriminalization of cannabis become increasingly widespread, the recreational, or adult-use, cannabis market alone reached about $15 billion last year.

According to MJBiz, legal marijuana sales are estimated to reach $33 billion by the end of 2022 and annual revenues are expected to hit $52 billion by 2026. The cannabis sector is rapidly expanding, with more states legalizing medicinal and recreational marijuana, including potentially significant markets like New Jersey. These favorable developments suggest now is the time to invest in cannabis stocks without waiting for legalization.

GrowGeneration Corp. (GRWG)

GrowGeneration owns and operates specialty retail hydroponic and organic garden centers, and with 63 retail and distribution centers, it is the nation’s largest hydroponic and organic garden product supplier. Although GrowGeneration is not a cannabis-only company, many of its products are utilized in growing cannabis.

The rising cannabis sector in the United States has fueled a surge in demand for hydroponics supplies, which are used to grow plants without soil and for organic gardening. The company’s other products include plant nutrients, farming soils, modern lighting technologies, and hydroponic and aquaponic equipment.

Green Thumb Industries Inc. (CNSX: GTII)

Green Thumb Industries (GTI) is a cannabis consumer packaged goods company and retailer that makes and distributes branded cannabis products including flowers, concentrates, edibles, and topicals under Beboe, Dogwalkers, Dr. Solomon’s, Good Green, Incredibles, and RYTHM brands. The company also owns and operates retail cannabis stores called Rise.

Green Thumb operates in 15 U.S. states, with 17 manufacturing facilities and several retail locations. The company saw enormous growth after Illinois’ legal recreational marijuana market opened for operation at the beginning of 2020 and Green Thumb has the option to expand into more states as demand and the industry grow, offering the company new avenues for growth.

InnoCan Pharma Corporation (CNSX: INNO)

InnoCan Pharma is a specialty pharmaceutical company based in Israel that specializes in the development of innovative CBD delivery methods. The company is developing a CBD drug delivery platform based on a unique controlled-release liposome in collaboration with Yissum, the commercial arm of The Hebrew University of Jerusalem, which it believes will result in much more effective and long-term therapeutic benefits.

InnoCan recently stated that the physicochemical characterization of their CBD Liposome medicinal product, which is an important part of the FDA application package, was completed successfully. InnoCan is also working on a revolutionary, breakthrough exosome-based technology with Ramot at Tel Aviv University that employs CBD to target both CNS indications and the COVID-19 Virus.

Further, the company is seeking veterinary medicine commercialization after discovering promising results in the treatment of a variety of disorders in dogs. InnoCan currently holds over 15 patents, and with the exclusive and non-exclusive licensing agreements signed in 2021, the company’s technology commercialization is continuing to move in the right direction. InnoCan’s current pipeline of technological and pharmaceutical products and solutions may provide considerable value to investors in the future.

Innovative Industrial Properties Inc. (IIPR)

Innovative Industrial Properties is a self-advised real estate investment company (REIT) that specializes in the acquisition, disposition, development, and administration of industrial properties leased to experienced, state-licensed cannabis growers. The property sale to Innovative Industrial gives the cannabis operator much-needed cash, which helps to ease the liquidity shortage for growing marijuana companies.

These lease agreements provide the company with a consistent revenue source. As with any REIT, Innovative Industrial distributes at least 90% of its taxable revenue, which makes it a good pick for income investors as well. As of April 28, the company owned 109 properties comprising an aggregate of approximately 8.1 million rentable square feet (including approximately 2.4 million rentable square feet under development or redevelopment) in 19 states.

Conclusion

Despite the challenges, the rising demand for cannabidiol for health and wellness applications is hastening market expansion while the growing understanding of cannabidiol’s medical benefits has become a reason for regulators to approve CBD for various purposes. With more favorable legal actions on the cards for the coming years, the cannabis sector seems well-positioned to grow. Investing in the right cannabis company could help investors enjoy lucrative returns in the future.

DISCLAIMERS: The author(s)/brand(s) is compensated to provide independent analysis of companies. The stock market is volatile and investors are advised to do their own research prior to making a decision. Market commentary is individual opinion and should not serve as any form of advice. You must always do your own research. “Future Markets Research Tank” and any pseudonyms or brands or accounts associated with it are digital brand names and do not seek to be any form of financial advisor or equity research organization. We may operate under a number of pseudonyms. We received monetary compensation for the content and thoughts presented above and that should be taken into account when reading any content presented. Do Not Use Any Information in Our Publications, social media channels or anything else associate with our brand to Make an Investment Decision. There is no information on our website or distributed otherwise that should be used as the basis for an investment decision. We do not act, directly or indirectly, in the capacity of any of the following and you should not construe our activities as involving any of the following: (a) investment advisor; (b) broker dealer; © broker; (d) dealer; (e) stock recommender; (f) stock picker; (g) finder; (h) securities trading expert; (i) financial planner; (j) engaging in the offer and sale of securities; (k) securities analyst; (l) financial analyst; (m) providing price targets or buy or sell recommendations. Our activities involve multiple potential and/or actual conflicts of interest — we receive monetary or securities compensation in the very securities we are promoting. The third party shareholder from which we receive compensation also has an actual conflict of interest since he or she or it is paying us securities compensation for promotion services and such non-affiliate third party shareholder may sell other shares held while we are promoting the issuer that issues the stock held by such third party shareholder. There are no implied or express warranties regarding the contents of our Publications.